Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09BOH
|
||||
| Former ID |
DIB006454
|
||||
| Drug Name |
Verubulin
|
||||
| Synonyms |
Azixa; Verubulin hydrochloride; EP-128495; MPC-6827; Apoptosis inducer (cancer), Myriad; Caspase inducer (cancer), Myriad; Cell cycle arrest inducer (cancer), Myriad; Tubulin inhibitor (cancer), Myriad
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Brain metastases [ICD-11: 2D50; ICD-10: C79.3; ICD-9: 198.3] | Phase 2 | [1] | ||
| Glioblastoma multiforme [ICD-11: 2A00.0; ICD-9: 191] | Phase 2 | [2] | |||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [1], [3] | |||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [4] | |||
| Company |
Maxim Pharmaceuticals Inc
|
||||
| Structure |
 |
Download2D MOL |
|||
| Formula |
C17H17N3O
|
||||
| Canonical SMILES |
N(c1nc(nc2c1cccc2)C)(C)c1ccc(cc1)OC
|
||||
| CAS Number |
CAS 827031-83-4
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Tubulin beta (TUBB) | Target Info | Modulator | [5] | |
| KEGG Pathway | Phagosome | ||||
| Gap junction | |||||
| Pathogenic Escherichia coli infection | |||||
| NetPath Pathway | FSH Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| EGFR1 Signaling Pathway | |||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | ||||
| Huntington disease | |||||
| Reactome | Regulation of PLK1 Activity at G2/M Transition | ||||
| Loss of Nlp from mitotic centrosomes | |||||
| Recruitment of mitotic centrosome proteins and complexes | |||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | |||||
| Anchoring of the basal body to the plasma membrane | |||||
| WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | ||||
| Pathogenic Escherichia coli infection | |||||
| Mitotic G2-G2/M phases | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
| REF 4 | ClinicalTrials.gov (NCT01285414) Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme. U.S. National Institutes of Health. | ||||
| REF 5 | Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.ChemMedChem.2014 Apr;9(4):847-54. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.